3 brokerages have issued twelve-month price objectives for UroGen Pharma's stock. Their URGN stock forecasts range from $11.00 to $26.00. On average, they expect UroGen Pharma's stock price to reach $19.00 in the next year. This suggests a possible upside of 157.1% from the stock's current price.
What are analysts' target prices for urogen pharma's stock?
1 analysts have issued 12-month target prices for UroGen Pharma's shares. Their forecasts range from $26.00 to $50.00. On average, they anticipate UroGen Pharma's stock price to reach $38.67 in the next year. This suggests a possible upside of 141.4% from the stock's current price.
What is the upside for urogen Pharma (UGN) stock?
Their forecasts range from $26.00 to $50.00. On average, they anticipate UroGen Pharma's stock price to reach $38.67 in the next year. This suggests a possible upside of 141.4% from the stock's current price. View analysts' price targets for UroGen Pharma or view top-rated stocks among Wall Street analysts.
What is UROGEN Pharma's mailing address?
UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at (646) 768-9780 or via email at [email protected].
Where can I buy urgn stock?
Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
/cdn.vox-cdn.com/uploads/chorus_image/image/61476613/usa_today_10551616.0.jpg)
Should I buy or sell UroGen Pharma stock right now?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last twelve months. There are currently 1 hold rating...
What is UroGen Pharma's stock price forecast for 2022?
3 Wall Street analysts have issued 12 month target prices for UroGen Pharma's stock. Their forecasts range from $11.00 to $26.00. On average, they...
How has UroGen Pharma's stock performed in 2022?
UroGen Pharma's stock was trading at $9.51 at the beginning of the year. Since then, URGN stock has decreased by 26.3% and is now trading at $7.01....
When is UroGen Pharma's next earnings date?
UroGen Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for UroGe...
How were UroGen Pharma's earnings last quarter?
UroGen Pharma Ltd. (NASDAQ:URGN) posted its quarterly earnings data on Monday, March, 21st. The company reported ($1.27) earnings per share (EPS) f...
Who are UroGen Pharma's key executives?
UroGen Pharma's management team includes the following people: Ms. Elizabeth A. Barrett , Pres, CEO & Director (Age 60, Pay $1.25M) ( LinkedIn P...
Who are some of UroGen Pharma's key competitors?
Some companies that are related to UroGen Pharma include CinCor Pharma (CINC) , Vanda Pharmaceuticals (VNDA) , Y-mAbs Therapeutics (YMAB) , Zea...
What other stocks do shareholders of UroGen Pharma own?
Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics...
When did UroGen Pharma IPO?
(URGN) raised $46 million in an initial public offering on Thursday, May 4th 2017. The company issued 3,500,000 shares at $12.00-$14.00 per share....
Is UroGen Pharma stock a Buy, Sell or Hold?
UroGen Pharma stock has received a consensus rating of buy. The average rating score is and is based on 3 buy ratings, 1 hold ratings, and 0 sell r...
What was the 52-week low for UroGen Pharma stock?
The low in the last 52 weeks of UroGen Pharma stock was 4.87. According to the current price, UroGen Pharma is 144.97% away from the 52-week low.
What was the 52-week high for UroGen Pharma stock?
The high in the last 52 weeks of UroGen Pharma stock was 19.53. According to the current price, UroGen Pharma is 36.16% away from the 52-week high.
What are analysts forecasts for UroGen Pharma stock?
The 4 analysts offering price forecasts for UroGen Pharma have a median target of 28.75, with a high estimate of 50.00 and a low estimate of 11.00....
What is UroGen RSU?
(Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units ("RSUs") to eleven new employees in connection with their employment with UroGen. These new team members will support the ongoing commercial launch of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the continued development o
When will UroGen report results?
(Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will report first quarter 2021 financial results on Thursday, May 13, 2021, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.
When is UroGen's earnings call 2021?
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / UroGen Pharma Ltd. (NASDAQ:URGN) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 8:30 AM Eastern Time.
UroGen Pharma Ltd ( URGN ) Stock Market info
Recommendations: Buy or sell UroGen Pharma stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the UroGen Pharma share forecasts, stock quote and buy / sell signals below.
Sunrise Resources Stock Forecast, "SRES" Share Price Prediction Charts
Villahome — Sunrise resources c.s. Site valued at $3 billion gross. Check this out.
About URGN
UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Analyst Forecast
According to 6 analysts, the average rating for UroGen Pharma stock is "Buy." The 12-month stock price forecast is 36.60, which is an increase of 399.32% from the latest price.
News
PRINCETON, N.J.-- (BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, to...
